IDEAYA Biosciences, Inc. (IDYA)
$31.63
Rating:
Recommendation:
-
| Symbol | IDYA |
|---|---|
| Price | $31.63 |
| Beta | 0.774 |
| Volume Avg. | 0.77M |
| Market Cap | 2.039B |
| Shares () | - |
| 52 Week Range | 13.29-33.24 |
| 1y Target Est | - |
| DCF Unlevered | IDYA DCF -> | |
|---|---|---|
| DCF Levered | IDYA LDCF -> | |
| ROE | -23.01% | Sell |
| ROA | -18.27% | Sell |
| Operating Margin | - | |
| Debt / Equity | 0.41% | Neutral |
| P/E | -15.97 | Strong Sell |
| P/B | 3.74 | Strong Buy |
Latest IDYA news
About
Download (Excel)IDEAYA Biosciences, Inc., a synthetic lethality-focused precision medicine oncology company, focuses on the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. The company's lead product candidates include IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase I clinical trial for patients with solid tumors having methylthioadenosine phosphorylase deletions; and IDE196, a protein kinase C inhibitor that is in Phase I/II clinical trial for genetically defined cancers having GNAQ or GNA11 gene mutations. Its preclinical pipeline includes various synthetic lethality programs targeting PARG inhibitor in tumors for patients having tumors with a defined biomarker based on genetic mutations and/or molecular signatures; Pol Theta inhibitors in tumors with BRCA or other homologous recombination deficiency mutations; and WRN inhibitors in tumors with high microsatellite instability. The company has a research collaboration agreement with Cancer Research UK and the University of Manchester to develop small molecule inhibitors of Poly (ADP-ribose) glycohydrolase; and a clinical trial collaboration and supply agreement with Pfizer Inc. for Phase I/II study in metastatic uveal melanoma, skin melanoma, and other solid tumors, as well as a strategic partnership with GlaxoSmithKline plc. IDEAYA Biosciences, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.